Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Completes Monogram Offer; Merger Will be Completed Today

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that its tender offer for all outstanding shares of common stock of Monogram Biosciences expired at midnight last night, and the firm expects to complete its $107 million purchase at the close of business today.

LabCorp said that 21,481,203 shares of Monogram were tendered, representing approximately 93 percent of the outstanding shares of Monogram. LabCorp said that it would promptly pay Monogram shareholders the $4.55 per share stipulated in the agreement, which was reached in June.

LabCorp also said that it would exercise the "top-up option" under the terms of the acquisition agreement, which will enable it to effect a short-form merger by the close of business today, without the need for a meeting of Monogram's stockholders. Each share not tendered and accepted for payment in the offer will be converted into the right to receive $4.55 in cash.

Monogram, which makes pharmacogenomic assays, including the Trofile assay, which helps physicians determine which patients would benefit from treatment with Pfizer's maraviroc (Selzentry) drug, will become a wholly-owned subsidiary of LabCorp and will cease trading on the Nasdaq after today.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.